Neumora Therapeutics, Inc. Common Stock
NMRAHealthcare|Biotechnology|US
$0.50
+0.02 (+3.35%)
DCF Value
$1.10
Tangible Book / Share
$0.24
Cash / Share
$0.63
Financials
Financial Snapshot
Market Cap
$94.6M
Enterprise Value
-$21.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$212.7M
Cash & Investments
$116.8M
Net Cash
$116.5M
Free Cash Flow (TTM)
-$180.5M
Operating CF (TTM)
-$180.5M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$116.8M
Quarterly Burn
$45.1M
Monthly Burn
$15.0M
Est. Runway
~2.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $192.0M | $409.2M | $371.9M | $454.0M | $307.6M | $182.5M | $116.8M | |
| Operating Cash Flow | -$26.8M | -$75.4M | -$114.9M | -$163.3M | -$182.9M | -$206.4M | -$180.5M | |
| Free Cash Flow | -$28.1M | -$76.2M | -$115.4M | -$163.4M | -$182.9M | -$206.4M | -$180.5M | |
| Capital Expenditure | -$1.3M | -$817.0K | -$511.0K | -$117.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $230.1M | $293.5M | $115.7M | $231.9M | $21.6M | $77.1M | $78.8M |
R&D Spending
R&D (TTM)
$153.1M
R&D Intensity
—
R&D Growth vs Prior
-13.1%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $87.1M | $212.8M | $104.7M | $142.7M | $200.9M | $176.1M | $153.1M | |
| SG&A | $8.4M | $24.5M | $31.1M | $44.8M | $62.5M | $60.1M | $53.2M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $668.0K | $0.00 | $5.0M | $5.0M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$668.0K | $0.00 | -$5.0M | -$5.0M | |
| R&D | $87.1M | $212.8M | $104.7M | $142.7M | $200.9M | $176.1M | $153.1M | |
| SG&A | $8.4M | $24.5M | $31.1M | $44.8M | $62.5M | $60.1M | $53.2M | |
| Operating Income | -$95.5M | -$237.3M | -$135.9M | -$188.2M | -$263.5M | -$241.2M | -$211.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.2M | $6.5M | |
| Pretax Income | -$99.3M | -$237.3M | -$130.9M | -$235.7M | -$243.6M | -$236.8M | -$212.7M | |
| Net Income | -$99.3M | -$237.3M | -$130.9M | -$235.9M | -$243.8M | -$236.9M | -$212.7M | |
| EPS (Diluted) | -0.65 | -1.56 | -0.86 | -1.49 | -1.53 | -1.45 | -1.23 | |
| EBITDA | -$95.4M | -$236.8M | -$130.3M | -$235.0M | -$243.0M | -$233.4M | -$207.1M | |
| Shares Out. (M) | 151.95 | 151.95 | 151.95 | 158.83 | 159.38 | 163.39 | 185.16 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192.0M | $409.2M | $240.9M | $374.0M | $142.1M | $182.5M | $116.8M | |
| Short-Term Investments | $0.00 | $0.00 | $130.9M | $79.9M | $165.4M | $0.00 | $0.00 | |
| Total Current Assets | $193.8M | $415.6M | $388.0M | $478.3M | $314.1M | $190.5M | $124.9M | |
| Total Assets | $197.9M | $429.3M | $426.2M | $496.2M | $317.0M | $191.0M | $125.2M | |
| Total Current Liabilities | $9.4M | $23.3M | $23.7M | $25.1M | $29.9M | $32.5M | $27.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $193.0K | $41.0K | |
| Total Liabilities | $292.3M | $754.5M | $873.1M | $27.1M | $29.9M | $87.2M | $80.7M | |
| Stockholders' Equity | -$94.4M | -$325.2M | -$446.9M | $469.1M | $287.1M | $103.9M | $44.5M | |
| Retained Earnings | -$99.3M | -$336.6M | -$467.5M | -$703.4M | -$947.2M | -$1.18B | -$1.28B |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$26.8M | -$75.4M | -$114.9M | -$163.3M | -$182.9M | -$206.4M | -$180.5M | |
| Capital Expenditure | -$1.3M | -$817.0K | -$511.0K | -$117.0K | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$28.1M | -$76.2M | -$115.4M | -$163.4M | -$182.9M | -$206.4M | -$180.5M | |
| Investing Cash Flow | -$11.2M | -$817.0K | -$168.0M | $64.4M | -$70.6M | $168.5M | $94.0M | |
| Financing Cash Flow | $230.1M | $293.5M | $115.7M | $231.9M | $21.6M | $77.1M | $78.8M | |
| Issuance of Stock | $3.2M | $960.0K | $0.00 | $233.4M | $13.7M | $19.9M | $20.8M | |
| Repurchase of Stock | -$2.0K | $0.00 | $0.00 | -$491.0K | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $55.9M | $0.00 | $0.00 | $0.00 | $0.00 | $57.2M | $38.8M | |
| Stock Based Comp. | $1.7M | $4.3M | $8.3M | $17.2M | $40.0M | $29.9M | $28.0M | |
| Net Change in Cash | $192.1M | $217.3M | -$167.2M | $133.0M | -$231.9M | $39.2M | -$7.7M |
Dilution Tracker
Shares Outstanding
188M
5-Year Share Growth
+7.5%
Stock Issuance (TTM)
$20.8M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 151.95 | 151.95 | 151.95 | 158.83 | 159.38 | 163.39 | 185.16 | |
| Change vs Prior % | — | 0.0% | 0.0% | 4.5% | 0.3% | 2.5% | 13.3% | |
| Stock Issuance | $3.2M | $960.0K | $0.00 | $233.4M | $13.7M | $19.9M | $20.8M | |
| Stock Repurchase | -$2.0K | $0.00 | $0.00 | -$491.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.7M | $4.3M | $8.3M | $17.2M | $40.0M | $29.9M | $28.0M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 105.2% | 73.0% | 29.3% | -50.3% | -84.9% | -228.1% | -242.3% | |
| ROA % | -50.2% | -55.3% | -30.7% | -47.5% | -76.9% | -124.0% | -169.9% | |
| ROIC % | -50.4% | -58.3% | -33.5% | -39.7% | -91.2% | -151.8% | -216.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | |
| Operating Income | 0.0% | 0.0% | -148.5% | 42.7% | -38.5% | -40.0% | 8.5% | |
| Net Income | 0.0% | 0.0% | -139.1% | 44.8% | -80.2% | -3.3% | 2.8% | |
| EPS (Diluted) | 0.0% | 0.0% | -140.0% | 44.9% | -73.3% | -2.7% | 5.2% | |
| Operating Cash Flow | 0.0% | 0.0% | -181.8% | -52.3% | -42.1% | -12.0% | -12.8% | |
| Free Cash Flow | 0.0% | 0.0% | -171.7% | -51.4% | -41.6% | -12.0% | -12.8% | |
| R&D Expense | 0.0% | 0.0% | 144.2% | -50.8% | 36.2% | 40.8% | -12.4% | |
| SG&A Expense | 0.0% | 0.0% | 192.5% | 26.8% | 44.0% | 39.6% | -3.9% | |
| Total Assets | 0.0% | 0.0% | 116.9% | -0.7% | 16.4% | -36.1% | -39.7% | |
| Book Value / Share | 0.0% | 0.0% | -244.6% | -37.4% | 200.4% | -39.0% | -64.7% | |
| Debt | 0.0% | 0.0% | 0.3% | 311.4% | -38.0% | -64.6% | -74.3% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 4.5% | 0.3% | 2.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.09
10Y Low / Med / High2.82 / 5.77 / 5.89
EV/EBITDA0.11
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.10
Tangible Book / Share
$0.24
Net Current Assets / Share
$0.23
Graham Net-Net
$0.19
Cash / Share
$0.63
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -25.00 | -10.42 | -18.90 | -11.44 | -6.93 | -1.23 | -0.41 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -26.16 | -7.59 | -5.53 | 5.77 | 5.89 | 2.82 | 2.09 | |
| EV/EBITDA | -23.89 | -8.71 | -17.16 | -9.95 | -6.38 | -0.47 | 0.11 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-18.14
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $625.0K | $2.9M | $3.0M |
| Net Income | -$136.3M | -$95.9M | -$105.0M |
| EPS | $-0.90 | $-0.62 | $-0.67 |
| # Analysts (EPS) | 7 | 7 | 8 |